THE DEAL, AT A GLANCE
From the announcementRatio Therapeutics
01Who is involvedBacked by Ratio's Trillium pharmacokinetic tuning technology, Macropa chelator platform, Portfolia Ventures, experienced biopharmaceutical industry leadersFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedRatio Therapeutics raised $70M Series C, announced 2026-07-31From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersRatio Therapeutics raised a $70M Series C to advance clinical development of its targeted radiotherapeutics pipeline and expand manufacturing infrastructure.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Ratio Therapeutics · Financing Record
Explore source-linked visual explanations for Ratio Therapeutics. Unsupported claims are withheld while source review continues.
Record 9393 · Recorded date: 2026-07-31
Explore company records →